Research progression on resistance mechanisms of epidermal growth factor receptor tyrosine kinase ;inhibitors in non-small cell lung cancer
10.3760/cma.j.issn.1673-422X.2015.03.012
- VernacularTitle:表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌的耐药机制
- Author:
Yun LIU
;
Jifeng FENG
;
Zhaoyue YAN
- Publication Type:Journal Article
- Keywords:
Receptor,epidermal growth factor;
Carcinoma,non-small-cell lung;
Drug resistance;
Liver X receptor
- From:
Journal of International Oncology
2015;(3):206-209
- CountryChina
- Language:Chinese
-
Abstract:
EGFR-TKI plays an important role in the treatment of non-small-cell lung cancer. However, some researchers find that there are still some patients with primary or acquired resistance to EGFR-TKI. The present known mechanisms of acquired drug resistance finally lead to the re-activation EGFR downstream signa-ling pathways. Liver X receptor agonist has inhibition function to several critical steps of EGFR downstream sig-naling pathways PI3K-Akt-NF-κB,which makes it possible to overcome the drug resistance.
